For prescribing information and adverse event reporting, click here

This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here

This website has been commissioned by Ipsen UK and is intended for a UK audience.

All materials

PREF-NET Study Overview: Patient Preference and Experience Study

Acromegaly / Neuroendocrine Tumours (NETs) File
15 pages

The PREF-NET study was a patient preference and experience study that demonstrated a strong preference among patients for home administration of Lanreotide Ipsen over hospital administration. For a detailed overview, explore the study summary.

LAN-UK-000611 | June 2025

PREF-NET Study Overview: Patient Preference and Experience Study
Explore more Acromegaly / Neuroendocrine Tumours (NETs) Resources

Explore more Acromegaly / Neuroendocrine Tumours (NETs) Resources

Browse

To access relevant information about Acromegaly / Neuroendocrine Tumours (NETs), please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 
01753 627777.

I am a patient

This section provides information to support patients that have been prescribed Lanreotide Ipsen.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 
01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.